The partial government shutdown, now the longest in U.S. history, began to take a bite out of biotech this week, served with a hot side dish of confusion. On Tuesday, Aimmune Therapeutics (NASDAQ: AIMT) said the shutdown would delay the review—and potential approval—of its experimental treatment for peanut allergy. Aimmune said it received a letter […]
Original Article: Bio Roundup: Aimmune Drama, Shutdown Blues, Perlmutter Talks Cancer